Related Experiment Video
Updated: Aug 17, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of
Ashwani Mehta1, Pradeep Jain2, Ravikant Patil3
1Cardiology, Dr Ashwani Mehta Clinic, New Delhi, IND.
Insights
Rosuvastatin effectively lowers cholesterol and improves lipid profiles in Indian patients for cardiovascular event prevention. This real-world study confirms its safety and efficacy in diverse patient groups.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Rosuvastatin is a potent statin for managing dyslipidemia by reducing cholesterol synthesis and modulating lipoprotein levels.
- Understanding real-world treatment patterns and outcomes of rosuvastatin is crucial for cardiovascular disease (CVD) prevention in India.
Purpose of the Study:
- To evaluate clinical characteristics and treatment patterns of rosuvastatin in Indian patients.
- To assess the effectiveness of rosuvastatin in primary and secondary prevention of cardiovascular events.
Main Methods:
- A retrospective, multi-centric observational study involving 1,816 adult patients treated with rosuvastatin or rosuvastatin-based combinations.
- Data collection included demographics, concomitant diseases, medications, and pre- and post-treatment lipid profiles.
- Analysis focused on treatment patterns, dosage, lipid-lowering efficacy, and adverse events.
Main Results:
- The study population (mean age 54.1 years) comprised 66.2% men; 71.9% received rosuvastatin for primary and 28.1% for secondary prevention.
- Rosuvastatin significantly reduced total cholesterol, triglycerides, and LDL cholesterol, while increasing HDL cholesterol (p<0.0001).
- Commonly prescribed doses were 10 mg for primary and 20 mg for secondary prevention; combination therapy was frequent (aspirin 34.0%, fenofibrate 21.9%).
Conclusions:
- Moderate- to high-intensity rosuvastatin (5-40 mg) is clinically effective and safe for primary and secondary CVD prevention in the Indian population.
- Statin therapy, including rosuvastatin, plays a vital role in reducing cardiovascular morbidity and mortality.
Abstract:
Background Rosuvastatin effectively reduces endogenous cholesterol synthesis and low-density lipoprotein (LDL) cholesterol and increases high-density lipoprotein (HDL) cholesterol. This study aimed to evaluate the clinical characteristics of patients and treatment patterns of rosuvastatin as a lipid-lowering therapy for primary and secondary prevention of cardiovascular events in Indian settings. Methods This real-world, retrospective multi-centric observational study included patients aged >18 years who received treatment with a rosuvastatin/rosuvastatin-based combination. Demographic and data about concomitant diseases and medications were recorded. Results Out of 1,816 patients, the majority were men (66.2%); the mean age was 54.1 years. The patients prescribed rosuvastatin for primary and secondary prevention of cardiovascular events were 71.9% and 28.1%, respectively. Rosuvastatin 10 mg (56.8%) was the most commonly prescribed dose. For primary prevention, 10 mg (65.0%) was the most preferred dose, and for secondary prevention, 20 mg (54.3%) was the most preferred dose. Rosuvastatin treatment significantly (pre- vs. post-treatment) reduced the levels of total cholesterol (227.2 vs. 178.4 mg/dL), triglycerides (212.6 vs. 154.4 mg/dL), and LDL cholesterol (167.0 vs. 125.6 mg/dL), and increased HDL cholesterol levels (40.7 vs. 44.3 mg/dL) (p<0.0001). A total of 1,196 patients received combination therapy with rosuvastatin (aspirin, 34.0%, and fenofibrate, 21.9%). Adverse events were reported in 0.4% of the study population (leg pain, nausea, muscle cramps/pain, bleeding, and myalgia). Conclusion This study demonstrated the clinical effectiveness and safety of moderate- to high-intensity rosuvastatin (5-40 mg) for primary and secondary prevention of cardiovascular events in the Indian population. A primary prevention strategy with statins can reduce cardiovascular events and associated morbidity and mortality.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications